A large Dutch randomized clinical trial (SUMMER) found that a widely marketed antioxidant supplement (Impryl) did not improve ongoing pregnancy rates in men seeking fertility care. Instead, pregnancy success was significantly lower in the critical 4–6 month treatment window, raising safety concerns.